Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
TNXP Stock Summary
Top 10 Correlated ETFs
TNXP
In the News
3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million
Here's the deal with stocks to turn $1,000 into $1 million: if you want to play, you gotta pay. I'm not just talking about the price of the securities themselves.
3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
In almost every situation, investors should stay away from penny stocks. They're extremely speculative and they tend to facilitate delusions of grandeur.
Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in January: Focus is on TNX-102 SL for the Management of Fibromyalgia Following Positive Topline Results in Second Pivotal Phase 3 Trial
TNX-102 SL is a Non-Opioid Analgesic that Demonstrated Daily Pain Reduction Over Placebo (Primary Endpoint, p = 0.00005) and Showed Positive Effects Across All Six Key Secondary Endpoints in Recently Reported Phase 3 Trial
Tonix Pharmaceuticals to Present at The National Academies Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures Public Meeting
CHATHAM, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Seth Lederman M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at the National Academies of Sciences, Engineering, and Medicine Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures public meeting on Thursday, December 14, 2023 via Zoom. Dr. Lederman will participate in a panel discussion on Vaccine Research & Development taking place from 2:00 - 2:45 p.m. ET.
Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in December
CHATHAM, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Tonix Management will present and host investor meetings at the following December investor conferences:
Tonix shares sink 29% on discontinued development on depression treatment
Shares of Tonix Pharmaceuticals TNXP fell Tuesday after the company said it would discontinue development of its treatment for major depressive disorder.
Tonix Pharmaceuticals to Present at the 2023 ThinkEquity Conference
CHATHAM, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Thursday, October 19, 2023, at 8:00 a.m. ET, and host investor meetings. The conference is being held at the Mandarin Oriental, New York in New York City.
Why Is Tonix Pharmaceuticals (TNXP) Stock Down 29% Today?
Tonix Pharmaceuticals (NASDAQ: TNXP ) stock is falling hard on Friday after the clinical-stage biopharmaceutical company priced a share offering. According to a press release from Tonix Pharmaceuticals, it has entered into a securities purchase agreement with certain healthcare institutional investors.
Tonix Pharmaceuticals to Present at the August Virtual Investor Summit
CHATHAM, N.J., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Gregory Sullivan, M.D., Chief Medical Officer of Tonix Pharmaceuticals, will present at the August 2023 Virtual Investor Summit on Thursday, August 24, 2023, at 10:00 a.m. ET.
Penny Stocks To Buy? 5 To Watch With Big News This Week
Investors often rely on stock market news to stay abreast of everything, ranging from low-cost penny stocks to industry giants such as Apple or Tesla. It's no secret that news can ignite excitement and skepticism in the blink of an eye, fueling speculation and thereby increasing market volatility.
TNXP Financial details
TNXP Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -16.05K | -3.53K | -106.54 | -51.2 | -3.22 | |
Operating cash flow per share | -14.75K | -3.32K | -102.69 | -41.95 | -2.74 | |
Free cash flow per share | -14.76K | -3.32K | -120.79 | -61.55 | -4.09 | |
Cash per share | 15.41K | 1.4K | 162.95 | 99.2 | 3.36 | |
Book value per share | 14.56K | 1.17K | 185.32 | 121.44 | 5.8 | |
Tangible book value per share | 14.49K | 1.16K | 185.07 | 121.44 | 5.8 | |
Share holders equity per share | 14.56K | 1.17K | 185.32 | 121.44 | 5.8 | |
Interest debt per share | 0 | 44.52 | 2.77 | 0.53 | -0.2 | |
Market cap | 7.15M | 1.88M | 64.32M | 129.68M | 87.2M | |
Enterprise value | -17.88M | -9.01M | -11.43M | -48.03M | -32.27M | |
P/E ratio | -0.27 | -0.07 | -1.28 | -1.41 | -0.76 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -0.3 | -0.07 | -1.32 | -1.72 | -0.89 | |
PFCF ratio | -0.3 | -0.07 | -1.13 | -1.17 | -0.6 | |
P/B Ratio | 0.3 | 0.2 | 0.73 | 0.59 | 0.42 | |
PTB ratio | 0.3 | 0.2 | 0.73 | 0.59 | 0.42 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 0.68 | 0.31 | 0.23 | 0.52 | 0.29 | |
EV to operating cash flow | 0.75 | 0.34 | 0.24 | 0.64 | 0.33 | |
EV to free cash flow | 0.75 | 0.34 | 0.2 | 0.43 | 0.22 | |
Earnings yield | -3.65 | -15.08 | -0.78 | -0.71 | -1.32 | |
Free cash flow yield | -3.35 | -14.19 | -0.89 | -0.85 | -1.68 | |
Debt to equity | 0 | 0.04 | 0.01 | 0 | 0 | |
Debt to assets | 0 | 0.02 | 0.01 | 0 | 0 | |
Net debt to EBITDA | 0.95 | 0.38 | 1.5 | 1.93 | 1.07 | |
Current ratio | 9.81 | 2.72 | 8.96 | 8.71 | 7.19 | |
Interest coverage | 0 | 0 | 0 | 0 | 14.17 | |
Income quality | 0.92 | 0.93 | 0.96 | 0.82 | 0.89 | |
Dividend Yield | 0.46 | 1.31 | 0.01 | 0 | 0.08 | |
Payout ratio | -0.13 | -0.09 | -0.01 | 0 | -0.06 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0.01 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0.18 | 0.47 | 0.49 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.11 | -0.65 | -317.19 | -706.14 | -38.43 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 72.53K | 9.64K | 666.5 | 374.02 | 20.49 | |
ROIC | -1.12 | -2.82 | -0.56 | -0.42 | -0.56 | |
Return on tangible assets | -1 | -1.97 | -0.51 | -0.38 | -0.51 | |
Graham Net | 14.01K | 790.94 | 144.71 | 87.95 | 2.9 | |
Working capital | 23.4M | 8.81M | 78.17M | 167.33M | 112.6M | |
Tangible asset value | 23.54M | 9.3M | 87.53M | 218.6M | 207.18M | |
Net current asset value | 23.4M | 8.81M | 77.45M | 166.87M | 112.27M | |
Invested capital | 0 | 0.04 | 0.01 | 0 | 0 | |
Average receivables | 509.5K | 768K | 4.32M | 7.68M | 7.88M | |
Average payables | 1.35M | 2.24M | 3.83M | 8.94M | 10.68M | |
Average inventory | 0 | -505.5K | -4.32M | -7.68M | -7.88M | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 19.47 | 38.87 | 33.23 | 52.52 | 26.27 | |
Days of inventory on hand | 0 | -12.8 | -55.11 | -30.55 | -26.19 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 18.75 | 9.39 | 10.99 | 6.95 | 13.89 | |
Inventory turnover | 0 | -28.51 | -6.62 | -11.95 | -13.94 | |
ROE | -1.1 | -3.01 | -0.57 | -0.42 | -0.56 | |
Capex per share | -3.69 | -2.11 | -18.11 | -19.6 | -1.35 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.23 | 0 | 3.34 | 0 | 0.26 | |
Net income per share | -0.68 | -0.61 | -3.08 | -2.68 | -1.83 | |
Operating cash flow per share | -0.56 | -0.36 | -3.25 | -2.21 | -1.53 | |
Free cash flow per share | -0.77 | -0.44 | -3.62 | -2.38 | -1.64 | |
Cash per share | 3.34 | 1.96 | 7.1 | 2.42 | 0.45 | |
Book value per share | 5.46 | 3.38 | 16.32 | 13.27 | 7.88 | |
Tangible book value per share | 5.46 | 3.38 | 16.32 | 12.21 | 7.17 | |
Share holders equity per share | 5.46 | 3.38 | 16.32 | 13.27 | 7.88 | |
Interest debt per share | 0.04 | 0 | -0.08 | 0.12 | 0.08 | |
Market cap | 138.84M | 149.77M | 37.4M | 16.73M | 8.35M | |
Enterprise value | -256.4K | 30.3M | -33.55M | -7.62M | 2.59M | |
P/E ratio | -1.22 | -1 | -0.3 | -0.15 | -0.07 | |
Price to sales ratio | 14.26 | 0 | 1.1 | 0 | 2.09 | |
POCF ratio | -5.9 | -6.72 | -1.14 | -0.72 | -0.36 | |
PFCF ratio | -4.29 | -5.55 | -1.02 | -0.66 | -0.33 | |
P/B Ratio | 0.61 | 0.72 | 0.23 | 0.12 | 0.07 | |
PTB ratio | 0.61 | 0.72 | 0.23 | 0.12 | 0.07 | |
EV to sales | -0.03 | 0 | -0.99 | 0 | 0.65 | |
Enterprise value over EBITDA | 0.01 | -0.93 | 0.99 | 0.27 | -0.09 | |
EV to operating cash flow | 0.01 | -1.36 | 1.02 | 0.33 | -0.11 | |
EV to free cash flow | 0.01 | -1.12 | 0.91 | 0.3 | -0.1 | |
Earnings yield | -0.2 | -0.25 | -0.83 | -1.7 | -3.35 | |
Free cash flow yield | -0.23 | -0.18 | -0.98 | -1.51 | -3.02 | |
Debt to equity | 0 | 0 | 0.01 | 0.01 | 0.01 | |
Debt to assets | 0 | 0 | 0.01 | 0.01 | 0.01 | |
Net debt to EBITDA | 4.74 | 3.65 | 2.09 | 0.87 | 0.2 | |
Current ratio | 11.33 | 7.19 | 6.4 | 2.78 | 1.77 | |
Interest coverage | -48.51 | 39.67 | 18.94 | 0 | 0 | |
Income quality | 0.81 | 0.7 | 1 | 0.82 | 0.84 | |
Dividend Yield | 0 | 0.02 | 0 | 0 | 0 | |
Payout ratio | 0 | -0.06 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.76 | 0 | 0.22 | 0 | 0 | |
Research and developement to revenue | 2.28 | 0 | 0.78 | 0 | 5.28 | |
Intangibles to total assets | 0 | 0 | 0 | 0.07 | 0.08 | |
Capex to operating cash flow | 0.37 | 0.21 | 0.12 | 0.08 | 0.08 | |
Capex to revenue | -0.91 | 0 | -0.11 | 0 | -0.45 | |
Capex to depreciation | -35 | -5.59 | -4.25 | -2 | -1.49 | |
Stock based compensation to revenue | 0.28 | 0 | 0.08 | 0 | 0.52 | |
Graham number | 9.11 | 6.79 | 33.63 | 28.28 | 17.99 | |
ROIC | -0.13 | -0.18 | -0.19 | -0.41 | -0.22 | |
Return on tangible assets | -0.12 | -0.17 | -0.17 | -0.19 | -0.22 | |
Graham Net | 3.01 | 1.69 | 5.75 | 1.25 | -0.24 | |
Working capital | 137.8M | 112.6M | 70.65M | 32.89M | 13.6M | |
Tangible asset value | 228.92M | 207.18M | 165.43M | 129.28M | 109.89M | |
Net current asset value | 137.42M | 112.27M | 70.07M | 32.06M | 12.89M | |
Invested capital | 0 | 0 | 0.01 | 0.01 | 0.01 | |
Average receivables | 0 | 4.02M | 4.02M | 0 | 781K | |
Average payables | 7.06M | 6.31M | 8.04M | 7.84M | 7.74M | |
Average inventory | 0 | -4.02M | -4.02M | 6.85M | 13.51M | |
Days sales outstanding | 0 | 0 | 0 | 0 | 35.24 | |
Days payables outstanding | 1.63K | 868.56 | 807.88 | 23.81 | 295.67 | |
Days of inventory on hand | 0 | -865.87 | 0 | 42.51 | 504.86 | |
Receivables turnover | 0 | 0 | 0 | 0 | 2.55 | |
Payables turnover | 0.06 | 0.1 | 0.11 | 3.78 | 0.3 | |
Inventory turnover | 0 | -0.1 | 0 | 2.12 | 0.18 | |
ROE | -0.12 | -0.18 | -0.19 | -0.2 | -0.23 | |
Capex per share | -0.21 | -0.08 | -0.37 | -0.17 | -0.12 |
TNXP Frequently Asked Questions
What is Tonix Pharmaceuticals Holding Corp. stock symbol ?
Tonix Pharmaceuticals Holding Corp. is a US stock , located in Chatham of Nj and trading under the symbol TNXP
What is Tonix Pharmaceuticals Holding Corp. stock quote today ?
Tonix Pharmaceuticals Holding Corp. stock price is $0.2182 today.
Is Tonix Pharmaceuticals Holding Corp. stock public?
Yes, Tonix Pharmaceuticals Holding Corp. is a publicly traded company.